Vaccine extends glioblastoma patients' survival in phase II trial
Thursday, October 7, 2010 - 10:00
in Health & Medicine
A vaccine that turns the immune system against brain tumour cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Centre reported today in the Journal of Clinical Oncology...